The company’s plans to prioritise research and development will see a 50% increase in the number of phase-three trials in 2024 and 2025, it said in a statement.

Its blockbuster asthma and skin medicine Dupixent is expected to see low double-digit net sales growth between 2023 to 2030, it said.

The statement comes hours before a high-stakes meeting with investors on Thursday, at which CEO Paul Hudson is expected to offer more details on the firm’s plan to sacrifice some earnings in the next couple of years to allow for greater R&D investment.

Hudson caused a record selloff in shares when he introduced the approach in October, with investors fearing that the resulting profit warning could signal a gloomier outlook for the company’s existing products.

Sanofi, however, argues that the strategy shift is a sign of strength. Houman Ashrafian, who joined as Sanofi’s head of R&D in September, praised the company’s clinical efforts of recent years but said it now needs to spend more to exploit its pipeline of experimental medicines.

At the event with investors, the company is expected to highlight its pipeline of 12 potential blockbuster drugs. Dupixent, which shows promise in treating a chronic lung disorder, is also likely to feature heavily.